Sigstad E, Lie A K, Luostarinen T, Dillner J, Jellum E, Lehtinen M, Thoresen S, Abeler V
Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway.
Br J Cancer. 2002 Jul 15;87(2):175-80. doi: 10.1038/sj.bjc.6600454.
Several prospective studies with invasive carcinoma as endpoint have supported Human Papillomavirus as a cause of cervical carcinoma. However, the largest study used seroepidemiology and did not analyse presence of Human Papillomavirus DNA in the subsequent tumour. Linkage of serum bank registries and cancer registries had identified 196 women with a registered cervical carcinoma after donation of a serum sample. For the present study, biopsies for 127 cases could be located, verified to contain invasive carcinoma and be amplified by PCR. Three control women who had remained alive and without cervical carcinoma during an equal length of follow-up had been matched to each of the case women and tested for HPV antibodies. Presence of Human Papillomavirus DNA in the tumours was analysed by general primer and type specific PCR. HPV16-seropositive women had a relative risk of 4.4 (95% CI: 2.2-8.8) to develop cervical carcinoma carrying HPV16 DNA. By contrast, there was no excess risk for Human Papillomavirus 16-seropositive women to develop cervical carcinoma devoid of HPV16 DNA. Prediagnostic HPV16 seropositivity was strongly correlated with later HPV16 DNA positivity of the tumour (P<0.001) and prediagnostic HPV18 seropositivity correlated with HPV18 DNA in the tumour (P<0.03). The link between prediagnostic seropositivity and type of viral DNA in the cancer implies that the carcinogenic effect of infection with these viruses is dependent on persistent presence of type-specific viral DNA.
几项以浸润性癌为终点的前瞻性研究支持人乳头瘤病毒是宫颈癌的病因。然而,规模最大的研究采用了血清流行病学,并未分析后续肿瘤中人乳头瘤病毒DNA的存在情况。血清库登记处与癌症登记处的关联已确定,有196名女性在捐献血清样本后被登记患有宫颈癌。在本研究中,能够找到127例病例的活检样本,经核实含有浸润性癌,并通过聚合酶链反应(PCR)进行扩增。在相同的随访期内,选取了3名存活且无宫颈癌的对照女性与每名病例女性进行匹配,并检测她们的人乳头瘤病毒(HPV)抗体。通过通用引物和型特异性PCR分析肿瘤中人乳头瘤病毒DNA的存在情况。HPV16血清反应阳性的女性患携带HPV16 DNA宫颈癌的相对风险为4.4(95%置信区间:2.2 - 8.8)。相比之下,HPV16血清反应阳性的女性患不携带HPV16 DNA宫颈癌的风险并未增加。诊断前HPV16血清反应阳性与后来肿瘤的HPV16 DNA阳性密切相关(P<0.001),诊断前HPV18血清反应阳性与肿瘤中的HPV18 DNA相关(P<0.03)。诊断前血清反应阳性与癌症中病毒DNA类型之间的联系表明,感染这些病毒的致癌作用取决于特定类型病毒DNA的持续存在。